Table 2

Univariate Cox regression analysis of variables associated with death in all patients after listing for liver transplantation

	Cox regression analysis Outcome death (censored at transplant)			Competing risk Cox regression analysis Outcome death
	HR	95% CI	p Value	HR	95% CI	p Value
Age (years)	0.99	0.97 to 1.02	0.543	1.01	0.99 to 1.04	0.317
Female gender	0.84	0.53 to 1.33	0.463	0.94	0.60 to 1.48	0.787
Blood group
A	1.25	0.78 to 1.99		1.11	0.70 to 1.76
B/AB	0.86	0.42 to 1.75	0.491	0.87	0.43 to 1.77	0.769
Body mass index >30 (kg/m²)	1.25	0.78 to 2.00	0.347	1.18	0.74 to 1.87	0.493
Hepatocellular carcinoma	0.66	0.28 to 1.51	0.322	0.52	0.23 to 1.16	0.111
eGFR <60 mL/min/1.73 m²	1.07	0.66 to 1.75	0.777	1.31	0.81 to 2.13	0.276
Hyponatraemia	2.79	1.78 to 4.36	<0.001	1.78	1.16 to 2.74	0.009
MELD score	1.14	1.09 to 1.19	<0.001	1.03	0.99 to 1.07	0.202
UKELD score	1.14	1.09 to 1.18	<0.001	1.05	1.01 to 1.10	0.029
Previous variceal haemorrhage	0.61	0.37 to 0.99	0.047	0.72	0.45 to 1.17	0.190
Refractory ascites	1.42	0.91 to 2.22	0.119	1.26	0.82 to 1.96	0.292
Prophylactic antibiotics	0.71	0.40 to 1.27	0.245	0.56	0.32 to 0.99	0.044
NSBB	0.52	0.34 to 0.82	0.004	0.68	0.44 to 1.04	0.076

p Value in bold indicates statistical significance.
Reference group (relative risk 1.00): male gender, blood group O, body mass index ≤30, no hepatocellular carcinoma, eGFR ≥60 mL/min/L.73 m², no hyponatraemia, no previous variceal haemorrhage, no refractory ascites, no prophylactic antibiotics and no NSBB.
eGFR, estimated glomerular filtration rate; MELD, model for end-stage liver disease; NSBB, non-selective β-blockers; UKELD, UK Score for Patients with End-Stage Liver Disease.